麻豆视频

Global Arteriotomy Closure Devices Market Trends and Insights

Increasing Prevalence of Cardiovascular & Peripheral Vascular Disorders

Global cardiovascular disease affected 655 million individuals in 2024, and peripheral arterial disease cases have risen 23% since 2010, resulting in sustained growth across diagnostic angiography, PCI, and peripheral interventions that all require reliable closure solutions.^{[1]JAMA Editors, 鈥淭ime to Hemostasis Comparative Study,鈥� jamanetwork.com} Procedure complexity in diabetic populations often demands repeat access, translating into steady, recurring demand within the arteriotomy closure devices market. Devices cut hemostasis time to around 1 minute versus 10 minutes for manual compression, allowing cath-labs to increase daily caseloads. Precision therapies targeting specific arterial beds likewise necessitate differentiated closure platforms, broadening the product mix that facilities must stock. Consequently, manufacturers that can offer comprehensive portfolios spanning sheath sizes from 5F to 24F are poised to capture incremental revenue.

Rising Geriatric Population & PCI Volumes

Patients older than 75 are the fastest-growing PCI cohort; comorbid calcification and anticoagulation elevate bleeding risk, making device-based closure preferable to manual compression. Outreach data show technical success rates of 94% and major complication rates below 1% when operators deploy closure systems in octogenarian cases.^{[2]PubMed Central, 鈥淭echnical Success of Closure Devices in Octogenarians,鈥� pubmed.ncbi.nlm.nih.gov} Same-day discharge adds further momentum, particularly since Medicare broadened outpatient PCI reimbursement in 2024. Health-systems also emphasize patient quality-of-life, and quicker ambulation lessens fall risk and hospital-acquired infections. Together these factors reinforce structural, long-term demand drivers for the arteriotomy closure devices market.

Rapid Uptake of Transradial & Same-Day Discharge Cath-Lab Programs

Same-day discharge rates for elective PCI reached 79% in leading cardiac centers by 2024, primarily due to dependable closure technologies that reduce observation times and nurse workload.^{[3]Journal of the American College of Cardiology, 鈥淎MBULATE Trial Findings,鈥� jacc.org} Financially, facilities save USD 1,500鈥�2,000 per case, a compelling incentive in value-based care environments. Electrophysiology procedures benefit strongly: the AMBULATE trial documented a 54% cut in time to ambulation and a 58% fall in opioid use when venous closure devices were utilized. COVID-19 constraints further accelerated adoption of outpatient models, prompting permanent infrastructural investments in standalone cath-labs equipped with modern closure tools. Regulatory guidance has now standardized discharge criteria, making same-day protocols routine rather than exception.

Growth in Large-Bore Interventions (TAVR, EVAR) Requiring Percutaneous Closure

TAVR volumes grew 15% year over year through 2024, and sheaths exceeding 20F require robust closure. Specialized devices priced three to four times higher than standard systems have achieved 98% arterial hemostasis with only 0.6% major vascular complications in prospective registries. Closing large arteriotomies eliminates surgical cut-downs, trimming procedure times by up to 34 minutes and supporting patient preference for minimally invasive approaches. As indications expand to intermediate-risk cohorts, the arteriotomy closure devices market gains a premium tailwind.

High ASPs of Active Closure Devices

Active closure systems range from USD 200 to 400 each, significantly above the USD 50-100 cost of manual compression kits. When large-bore TAVR cases require multiple devices, per-procedure spend can exceed USD 1,000, straining budgets in price-sensitive regions. Although bundled purchasing can offset inpatient days saved, public hospitals in emerging markets often lack capital flexibility, slowing penetration outside tier-one centers.

Device-Related Complications & Steep Learning Curve

Pseudoaneurysm, arterial occlusion, and infection are infrequent yet severe events that demand surgical intervention if closure fails. Data show a pronounced learning curve, with complication rates falling only after operators complete roughly 30 cases. Smaller facilities without sustained volumes may therefore default to manual compression. Manufacturers continue to expand proctor programs and simplify deployment mechanisms, yet operator proficiency remains a gating factor to broader uptake.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Active Devices Maintain Scale; Passive Devices Accelerate

Active platforms accounted for 58.62% of 2025 revenue within the arteriotomy closure devices market, primarily due to suture-mediated systems that span 5F-21F sheath sizes and achieve a 97.5% technical success rate in real-world registries. Their immediate hemostasis supports cath-lab throughput, and broad procedural coverage underpins their market leadership. 

Passive solutions, however, are expected to post an 11.49% CAGR through 2031, as bio-absorbable polymers address previous concerns over retained collagen plugs. Early clinical experience suggests 1-minute average hemostasis and rapid resorption within 30 days, which helps passive entries secure an incremental share, particularly in younger and bariatric populations where foreign-body avoidance is paramount.

By Application: Femoral Dominance Persists; Large-Bore Access Surges

Femoral arterial interventions accounted for 61.05% of the 2025 demand, aligning with the entrenched provider familiarity and anatomy that accommodates diverse sheath sizes. Facilities embracing same-day discharge appreciate the 1-2 minute closure times that femoral devices achieve compared to 8-15 minutes via manual compression, which enables daily lab throughput. 

Large-bore applications are poised for a 9.26% CAGR, mirroring the 15% annual rise in TAVR usage and continued EVAR adoption. Percutaneous closure of 24F arteriotomies eliminates the need for surgical cutdowns and shortens case times by up to 34 minutes, presenting high-margin revenue streams for suppliers in the arteriotomy closure devices market.

By End User: Hospitals Lead; Ambulatory Centers Disrupt

Hospitals accounted for 53.72% of 2025 sales, driven by their comprehensive trauma management capabilities and close collaboration with device manufacturers for training and adoption. Bundled payments that penalize readmissions further motivate hospitals to prefer devices over manual compression when the risk of bleeding is elevated. 

Ambulatory surgical and catheterization centers are expected to log a 10.02% CAGR. Their dependence on swift ambulation places closure-system performance at the heart of operational economics; devices that reduce observation windows from 6 to 12 hours to 2 to 4 hours directly expand daily case capacity and enhance patient satisfaction.

Geography Analysis

North America captured 42.98% of 2025 global revenue in the arteriotomy closure devices market. Medicare and private insurers reimburse closure tools without added patient cost, prompting universal adoption for PCI and electrophysiology procedures. United States operators also cite medico-legal imperatives favoring device-based closure to minimize bleeding complications. Canada鈥檚 single-payer model supports closure uptake where cost-utility studies show diminished inpatient days, while Mexico鈥檚 growing private hospital sector is upgrading cath-lab capabilities aligned with premium closure technologies.

Europe remains a mature but sizeable arena characterized by stringent evidence requirements and value-oriented purchasing frameworks. Germany leads implantation volumes; the United Kingdom quickly embraces cost-effective plug-based devices; and France and Italy sustain steady growth due to high procedural load and favorable coding for same-day discharge. Post-Brexit regulatory divergence complicates product registration timelines, yet EU MDR certification continues to promote technology differentiation on safety credentials.

Asia Pacific is projected to deliver the fastest regional CAGR of 8.83% to 2031 on the back of expanding cardiac care infrastructure and rising incidence of ischemic heart disease. China鈥檚 investment in public and private cath-labs accelerates volume growth, while domestic device players increasingly partner with global leaders for technology transfer. Japan鈥檚 advanced reimbursement and procedural sophistication underpin early adoption of bio-absorbable closure platforms. India鈥檚 demand outlook remains robust, albeit tempered by acute price sensitivity that requires tiered product offerings and lean distribution.

Regulatory Landscape

In the United States, large-bore vascular closure systems are regulated as Class III devices under the FDA Premarket Approval (PMA) pathway, while many lower-risk closure products proceed via 510(k) clearance. This high-barrier PMA route is used for next-generation large-bore platforms, as shown by Vivasure Medicals June 2025 PMA submission for PerQseal Elite. In Europe, market access is anchored on CE certification under the EU Medical Device Regulation (MDR), which raises requirements for clinical evidence, post-market clinical follow-up, and technical documentation compared with the legacy directives. MDR transition provisions and milestone-based timelines shape continuity of supply for established portfolios, while international expectations around biocompatibility and thrombogenicity testing, including the ISO 10993 series, remain central for materials used in collagen, PEG, and polymer or sealant-based closure systems.

Market Opportunities and Future Outlook

Whitespace is expanding in large-bore and mid-bore access management as hospitals and ambulatory cath-lab centers operationalize same-day discharge pathways and place a premium on fast hemostasis with fewer access-site complications. Recent regulatory actions reinforce this direction: the FDA approved Haemonetics VASCADE MVP XL for 8-14F inner diameter sheath access sites in March 2026, and CyndRx received FDA approval in June 2026 for its AbsorbaSeal vascular closure device for acute arterial access site closure. In July 2026, xDot Medical obtained an FDA IDE to start a pivotal trial targeting large-bore femoral arterial and venous access sites.

Technology opportunities focus on reducing retained-implant concerns and improving consistency across operators, aligning with the report themes around bio-absorbable or polymer sealants and simplified deployment. An April 2026 publication evaluating plug-based closure devices in TAVR using VARC-3-defined vascular endpoints also points to continued clinical evaluation informing product choices, and it highlights a practical near-term commercialization focus on evidence packages tied to time-to-ambulation and discharge eligibility while extending labeled sheath ranges and indications to reflect multi-access needs across electrophysiology, structural heart, and peripheral interventions.